



# Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study—TROG 18.06

Nathaniel Barry<sup>1,2</sup> · Roslyn J. Francis<sup>3,4</sup> · Martin A. Ebert<sup>1,2,4,5</sup> · Eng-Siew Koh<sup>6,7</sup> · Pejman Rowshanfarzad<sup>1,2</sup> · Ghulam Mubashar Hassan<sup>1</sup> · Jake Kendrick<sup>1,2</sup> · Hui K. Gan<sup>8,9,10,11</sup> · Sze T. Lee<sup>9,10,11,12</sup> · Eddie Lau<sup>12,13,14</sup> · Bradford A. Moffat<sup>14</sup> · Greg Fitt<sup>13</sup> · Alisha Moore<sup>15</sup> · Paul Thomas<sup>16,17</sup> · David A. Pattison<sup>16,17</sup> · Tim Akhurst<sup>10,18</sup> · Ramin Alipour<sup>10,18</sup> · Elizabeth L. Thomas<sup>3</sup> · Edward Hsiao<sup>19</sup> · Geoffrey P. Schembri<sup>19</sup> · Peter Lin<sup>7,20</sup> · Tam Ly<sup>20</sup> · June Yap<sup>20</sup> · Ian Kirkwood<sup>21,22</sup> · Wilson Vallat<sup>21</sup> · Shahroz Khan<sup>23</sup> · Dayanethee Krishna<sup>23</sup> · Stanley Ngai<sup>24</sup> · Chris Yu<sup>24</sup> · Scott Beuzeville<sup>25</sup> · Tow C. Yeow<sup>25</sup> · Dale Bailey<sup>19,26</sup> · Olivia Cook<sup>15</sup> · Angela Whitehead<sup>15</sup> · Rachael Dykyj<sup>15</sup> · Alana Rossi<sup>15</sup> · Andrew Grose<sup>15</sup> · Andrew M. Scott<sup>9,10,11,12</sup>

Received: 27 May 2023 / Accepted: 28 July 2023 / Published online: 11 August 2023  
© The Author(s) 2023, corrected publication 2023

## Abstract

**Purpose** The O-(2-[<sup>18</sup>F]-fluoroethyl)-L-tyrosine (FET) PET in Glioblastoma (FIG) trial is an Australian prospective, multi-centre study evaluating FET PET for glioblastoma patient management. FET PET imaging timepoints are pre-chemoradiotherapy (FET1), 1-month post-chemoradiotherapy (FET2), and at suspected progression (FET3). Before participant recruitment, site nuclear medicine physicians (NMPs) underwent credentialing of FET PET delineation and image interpretation.

**Methods** Sites were required to complete contouring and dynamic analysis by  $\geq 2$  NMPs on benchmarking cases ( $n = 6$ ) assessing biological tumour volume (BTV) delineation ( $3 \times$  FET1) and image interpretation ( $3 \times$  FET3). Data was reviewed by experts and violations noted. BTV definition includes tumour-to-background ratio (TBR) threshold of 1.6 with crescent-shaped background contour in the contralateral normal brain. Recurrence/pseudoprogression interpretation (FET3) required assessment of maximum TBR ( $TBR_{max}$ ), dynamic analysis (time activity curve [TAC] type, time to peak), and qualitative assessment. Intraclass correlation coefficient (ICC) assessed volume agreement, coefficient of variation (CoV) compared maximum/mean TBR ( $TBR_{max}/TBR_{mean}$ ) across cases, and pairwise analysis assessed spatial (Dice similarity coefficient [DSC]) and boundary agreement (Hausdorff distance [HD], mean absolute surface distance [MASD]).

**Results** Data was accrued from 21 NMPs (10 centres,  $n \geq 2$  each) and 20 underwent review. The initial pass rate was 93/119 (78.2%) and 27/30 requested resubmissions were completed. Violations were found in 25/72 (34.7%; 13/12 minor/major) of FET1 and 22/74 (29.7%; 14/8 minor/major) of FET3 reports. The primary reasons for resubmission were as follows: BTV over-contour (15/30, 50.0%), background placement (8/30, 26.7%), TAC classification (9/30, 30.0%), and image interpretation (7/30, 23.3%). CoV median and range for BTV,  $TBR_{max}$ , and  $TBR_{mean}$  were 21.53% (12.00–30.10%), 5.89% (5.01–6.68%), and 5.01% (3.37–6.34%), respectively. BTV agreement was moderate to excellent (ICC = 0.82; 95% CI, 0.63–0.97) with good spatial (DSC =  $0.84 \pm 0.09$ ) and boundary (HD =  $15.78 \pm 8.30$  mm; MASD =  $1.47 \pm 1.36$  mm) agreement.

**Conclusion** The FIG study credentialing program has increased expertise across study sites.  $TBR_{max}$  and  $TBR_{mean}$  were robust, with considerable variability in BTV delineation and image interpretation observed.

**Keywords** FET PET · Glioblastoma · Inter-observer · Credentialing · Clinical trials

✉ Nathaniel Barry  
Nathaniel.barry@research.uwa.edu.au

Extended author information available on the last page of the article

## Introduction

Glioblastoma (GBM) is the most common primary brain malignancy and has an exceptionally poor prognosis. Those who undergo a maximal tumour resection followed by combined radiochemotherapy, as per standard of care, have a 5-year survival rate of less than 10% [1]. The excellent soft tissue contrast of magnetic resonance imaging (MRI) is routinely used clinically to assist in GBM diagnosis, treatment planning, and response assessment [2, 3]. In the post treatment setting, however, MRI is associated with a lower specificity in identifying neoplastic lesions, limiting its diagnostic power [4]. Advanced MRI sequences such as perfusion and diffusion-weighted imaging may also be used, but the routine clinical availability of these sequences can vary [3, 5, 6].

Positron emission tomography (PET) paired with amino acid tracers has seen increased utilisation for clinical management of GBM. In particular, O-(2-[ $^{18}\text{F}$ ]-fluoroethyl)-L-tyrosine (FET) PET imaging has shown promise, due to its ideal half-life (110 min) and imaging characteristics. This includes superior tumour-to-background contrast when compared to the commonly used glucose analogue [ $^{18}\text{F}$ ]-2-fluoro-2-deoxy-D-glucose (FDG) PET [7]. Emerging literature has shown that combined FET PET and MRI has increased performance in primary/differential diagnosis compared to MRI alone [8–10]. For treatment planning, volumes derived from FET PET are typically larger and often encapsulate the respective MR-derived gross tumour volume. Although dose escalation based on FET PET has not shown survival benefit, its complimentary use in defining tumour burden has been well investigated [11–15].

Contrast enhancement on MRI depends on disruption of the blood–brain barrier; therefore, assessment of progressive disease is difficult when this same phenomenon can be caused by patient treatment. Since FET uptake within the brain does not require disruption of the blood–brain barrier, it has been shown to supplement the lack of specificity on contrast-enhanced T1-weighted MRI (T1c) when attempting to differentiate tumour recurrence from pseudoprogression or treatment-related change [16–20]. Quantitative FET PET static and dynamic metrics, including relative change in these metrics from baseline to follow-up, have exhibited significant prognostic power [21–25]. Furthermore, the Response Assessment in Neuro-Oncology (RANO) Working Group has advocated for the supplementary clinical use of PET imaging in glioma and brain metastasis [4, 26]. To date, the published literature has been limited to small, single centre retrospective and prospective studies. Since FET PET is likely to play a major role in glioma management in the future, its impact will need to be evaluated across multiple centres.

The O-(2-[ $^{18}\text{F}$ ]-fluoroethyl)-L-tyrosine (FET) PET in Glioblastoma (FIG) trial is an Australian, prospective, multi-centre

study designed to evaluate the impact of FET PET imaging in GBM management [27]. There are two primary objectives of the FIG study: to investigate how the addition of FET PET imaging to standard MRI imaging affects radiation target volume delineation and treatment planning for GBM, and to determine the accuracy and management impact of FET PET in distinguishing pseudoprogression from true tumour progression and/or tumour recurrence. This study is actively recruiting participants that will undergo FET PET imaging at three timepoints of interest: pre-chemoradiotherapy (FET1), 1-month post-chemoradiotherapy (FET2), and at suspected progression (FET3). Prior to enrolling participants into the prospective phase, each recruiting centre was required to undergo pre-trial quality assurance consisting of an initial credentialing phase. The nuclear medicine physician (NMP) contour data resulting from this credentialing phase have been incorporated into a study on inter-observer variability. Here, we summarise and assess NMP performance on image analysis at FET1 and FET3 as part of credentialing, with further quantitative investigation of variability in the following: volumetric assessment with FET PET, conventional quantitative metrics extracted from these volumes, background assessment, spatial overlap, and boundary agreement.

## Methods and materials

### Credentialing dataset

Six anonymised, representative FET PET scans, acquired with standardised protocols, were used for the credentialing study. Three FET scans were post-surgical delineation cases (FET1CASE1, FET1CASE2, and FET1CASE3, respectively) and three FET scans were obtained at suspected progression (FET3CASE1, FET3CASE2, and FET3CASE3, respectively). The six cases were representative of typical clinical cases for each scenario and were distinct in terms of intensity of uptake, location, biological tumour volume (BTV), and diagnosis. Relevant clinical information was available for each case (Table 1) and an instruction manual was provided to all NMPs who were performing the analysis (Supplementary Material 1). In accordance with the FIG study, imaging at FET2 is not directly assessed. It is, however, made available as previous imaging, when assessing treatment response at FET3. As such, this timepoint was not included for credentialing.

### Image acquisition/details

The credentialing scans were obtained from two sites, using a standardised imaging protocol. Images from the FET1 cases were taken from Sir Charles Gairdner Hospital, Western Australia (Human Research Ethics Committee approved

**Table 1** Clinical characteristics of the six nuclear medicine credentialing cases

Case	Sex/age	Localisation	Treatment <sup>a</sup>
FET1CASE1	F, 58	Right frontoparietal	Partial resection
FET1CASE2	M, 67	Right temporal	Gross total resection
FET1CASE3	F, 60	Left frontoparietal	Resection <sup>b</sup>
FET3CASE1	F, 55	Left parietal	Subtotal resection + 60 Gy/30 fractions + veliparib <sup>c</sup> /temozolomide
FET3CASE2	M, 37	Left parietal	Near gross total resection + 60 Gy/30 fractions + temozolomide
FET3CASE3	M, 59	Right temporoparietal	Near gross total resection + 60 Gy/30 fractions + temozolomide

N/A not available, M male, F female

<sup>a</sup>Completed at time of imaging

<sup>b</sup>Extent not specified

<sup>c</sup>Patient from the VERTU trial (ACTRN12615000407594)

study 2014–004). Images from the FET3 cases were taken from Royal North Shore Hospital, New South Wales (all subjects gave written informed consent for their data to be used). Patients were required to fast for a minimum of 4 h prior to imaging. Scans were taken, following intravenous administration of 200 MBq of FET, on a Biograph 16 PET/CT, Siemens (CTI Inc., Knoxville, TN). A low-dose CT was performed, immediately after administration, for attenuation correction. A dynamic acquisition followed (FET1 30-min acquisition, FET3 40-min acquisition) with the final static image consisting of the summed PET data (FET1 20–30 min, FET3 20–40 min) post-injection of tracer. Dead time, attenuation, scatter, decay, and random corrections were applied, along with detector normalisation. Iterative reconstruction for the FET1 cases was performed with point-spread function (PSF) applied (TrueX): 3 iterations, 24 subsets, matrix size =  $168 \times 168$ , zoom factor = 2, post-reconstruction filter = 4 mm full width at half maximum (FWHM) Gaussian kernel. Images were reconstructed to a voxel spacing of  $2.03135 \times 2.03135 \times 3 \text{ mm}^3$ . Iterative reconstruction for the FET3 cases was performed with PSF (TrueX), and time-of-flight (TOF) applied: 2 iterations, 21 subsets, matrix size =  $400 \times 400$ , zoom factor = 2, post-reconstruction filter = 2 mm FWHM Gaussian kernel. Images were reconstructed to a voxel spacing of  $2.03642 \times 2.03642 \times 3 \text{ mm}^3$ .

### Contouring protocol and dynamic analysis

At least two NMPs from each of the 10 selected study sites completed BTV delineation on all six cases. NMPs were required to delineate each case in accordance with the FIG study imaging and radiotherapy quality assurance manual as per the study protocol and using a MiM workflow developed for the FIG study (MiM Encore version 7.0, MiM Software Inc., Cleveland, OH). Briefly, delineation of the BTV followed a semi-automatic procedure. Background assessment was achieved by placing a crescent-shaped volume of interest (VOI), including grey and white matter, in the

hemisphere contralateral to the suspected lesion [28]. Background is defined as the mean standardised uptake value (SUV),  $\text{SUV}_{\text{mean}}$ , for that VOI. Amino acid uptake in the BTV was defined using a 1.6 tumour-to-background ratio (TBR) threshold on a spherical VOI (Static VOI) placed around the suspected tumour [29]. The segmented volume was then manually adjusted, if required, to remove any obvious non-tumour structures (e.g. scalp, sinus uptake). For the purposes of this study, the volume obtained after thresholding, but prior to manual adjustment, was referred to as GTV0. The final volume is referred to as the BTV.  $\text{TBR}_{\text{max}}$  was calculated by dividing the maximum SUV ( $\text{SUV}_{\text{max}}$ ) of the BTV by  $\text{SUV}_{\text{mean}}$  of the background and  $\text{TBR}_{\text{mean}}$  was calculated by dividing  $\text{SUV}_{\text{mean}}$  of the BTV by  $\text{SUV}_{\text{mean}}$  of the background. Lastly, as part of the dynamic analysis, a 1-mL spherical VOI was automatically generated and centred on  $\text{SUV}_{\text{max}}$  in the BTV to create a time activity curve (TAC) from the dynamic data. Time to peak (TTP) was calculated and NMPs were instructed to classify TACs into three types for each case, as described previously [30].

### Credentialing and analysis of violations

Each set of structures and dynamic analysis was submitted to the Trans-Tasman Radiation Oncology Group (TROG) for expert NMP review. The NMPs from each site had a range of experience in FET PET review and analysis. The 21 NMPs involved in the credentialing program were all experienced, with four having 5–9 years of clinical experience and 17 having over 10 years of clinical experience. In contrast, there was a wide range of NMP prior familiarity with FET PET analysis and interpretation, with seven NMPs having zero experience, eight having minimal experience, two having moderate experience, and four having significant experience. Expert review of each report was performed by one of three NM specialists (STL, RJF, EL) with clinical experience in FET PET contouring, interpretation, and analysis. As part of credentialing, protocol compliance was assessed

as acceptable, minor, or major based on BTV delineation (FET1 cases) and response interpretation (FET3 cases). Interpretation was informed by an initial qualitative assessment, which was reported descriptively as either suggestive of tumour progression or favouring treatment predominant changes. In conjunction, quantitative parameters were calculated from the FET3 cases, including  $TBR_{max}$ , TTP, and TAC type [17]. Both were combined to inform clinical response interpretation as either treatment predominant changes, equivocal, or consistent with tumour progression. In clinical practice, comparison with previous findings is crucial to interpretation, which will be conducted in the FIG study. However, no available study matched the design of the FIG study when developing the credentialing dataset; hence, previous imaging (i.e. FET1 and FET2) was not available to NMPs when evaluating the FET3 cases. NMPs were asked to resubmit to address major violations in protocol compliance. The rate and reason for minor/major violations were documented and resubmission rate was recorded. The expert comments provided to each NMP were then processed and analysed to assess the frequency of violation reasons. As part of this analysis, violation reasons were categorised and defined as follows: (1) BTV under-contouring where the NMP has failed to include important areas of uptake, (2) BTV over-contouring where the NMP has applied an unnecessary manual increase of the BTV and/or failed to remove non-tumour structures after thresholding, (3) incorrect background placement on the white–grey matter junction, (4) incorrect classification of TACs into type I, II, or III, and (5) image interpretation not concordant with reviewer.

## Statistical analysis

Descriptive statistics are reported as the mean/standard deviation, median/range, and coefficient of variation (CoV). The CoV is a normalised measure of variability to compare metrics between cases with differing means ( $CoV = \text{standard deviation}/\text{mean}$ ). Delineated structures were exported from MiM in DICOM RTStruct format and converted to NIfTI binary masks using Plastimatch, an open-source software for image computation.<sup>1</sup> To assess volume overlap, pairwise analysis was conducted between each NMP per case, measured using the Dice similarity coefficient (DSC). Furthermore, since DSC does not assess boundary differences, pairwise Hausdorff distance (HD) and mean absolute surface distance (MASD) were calculated. This combination of metrics adequately assesses contouring variations required for this analysis [31]. The pairwise analysis was computed using PlatiPy.<sup>2</sup> Lastly, the intraclass correlation coefficient (ICC)

is calculated to assess inter-observer reliability of contours using a two-way mixed model (absolute agreement, single rater/measurement) [32, 33]:

$$ICC(2, 1) = \frac{MS_R - MS_E}{MS_R + (k - 1)MS_E + \frac{k}{n}(MS_C - MS_E)}$$

where  $MS_R$  is the mean square for rows (between subjects),  $MS_E$  is the mean square for error,  $MS_C$  is the mean square for columns (between raters/measurements),  $n$  is the number of subjects, and  $k$  is the number of raters/measurements. The ICC ranges from 0 to 1, with 1 being perfect reliability. Here, the ICC is interpreted based on the 95% confidence intervals (CI below 0.5 is poor; 0.5 to 0.75 is moderate; 0.75 to 0.9 is good; above 0.9 is excellent), as per recommendations of Koo and Li [34]. The ICC was calculated in Python using the psych package (version 2.2.5) from R. The rpy2<sup>3</sup> interface was implemented to run R within a Python process.


## Results

Twenty-one NMPs from 10 centres submitted data for credentialing. One expert did not undergo review and a reporting physician contoured FET1CASE1 instead of FET1CASE3 in one instance which was not discovered during review and was subsequently passed. This incorrect submission was not included in further analysis. In total, 146 case reviews were conducted which included 119 initial submissions and an additional 27/30 resubmissions. The reports of three resubmissions were incomplete at the time of analysis. In three instances, two resubmissions were required. Reporting NMPs with zero or minimal prior experience with FET PET accounted for 26/30 (86.7%) requested resubmissions. The resulting performance of NMPs and recorded violations are shown in Fig. 1. Overall, a pass rate of 93/119 (78.2%) on the initial submissions was observed, with some form of violation in 25/72 (34.7%; 13 minor/12 major) of the FET1 submissions and 22/74 (29.7%; 14 minor/8 major) of the FET3 submissions. Overall, the 30 resubmissions that were requested by the expert reviewers were often triggered by either BTV over-contouring (15/30, 50.0%), an error in background placement (8/30, 26.7%), an error in TAC classification (9/30, 30.0%), or image interpretation not concordant with expert (7/30, 23.3%). It should be noted that these sources of violation are not mutually exclusive and there are some instances where reviewers provided multiple reasons when giving feedback to reporting NMPs. A summary of the case reviews can be found in Supplementary Material 2 Table S1.

<sup>1</sup> <http://plastimatch.org/> (version 1.9.0).

<sup>2</sup> <https://github.com/pyplati/platipy> (version 0.4.1).

<sup>3</sup> <https://rpy2.github.io/> (version 3.5.4).



**Fig. 1** An overview of NMP credentialing by expert reviewers and their sources of violations of the two key assessments during credentialing: FET1 BTV delineation and FET3 image interpretation. The frequency of acceptable, minor, and major violations is shown for FET1 (a) and FET3 (c), with violations split into

initial, first resubmission, and second resubmission. Frequency of FET1 (b) and FET3 (d) violation reasons, accrued from reviewer comments, is shown. Violation reasons are also broken down into reports that requested resubmissions to highlight NMP critical errors

For the quantitative assessment of NMP agreement, 125/126 structure sets (BTV, GTV0, Background, Static VOI) were available for analysis. If an NMP resubmitted contours, their final submission was used. All calculated metrics for the BTV are shown in Table 2. Variability of the BTV gave a median CoV of 21.53% (range, 12.00–30.10%). Variation in BTV delineation was lowest for FET1CASE2 ( $64.69 \pm 7.76 \text{ cm}^3$ ) and highest for FET3CASE2 ( $68.32 \pm 20.56 \text{ cm}^3$ ). Boxplots visualising the distribution of BTV,  $\text{TBR}_{\text{max}}$ , and  $\text{TBR}_{\text{mean}}$  by each case are shown in Fig. 2. Both  $\text{TBR}_{\text{max}}$  (CoV median, 5.89%; range, 5.01–6.68%) and  $\text{TBR}_{\text{mean}}$  (CoV median 5.01%; range, 3.37–6.34%) had similar variability across cases. The ICC was calculated from 20/21 NMPs and inter-observer agreement was found to be moderate to excellent ( $\text{ICC} = 0.82$ ; 95% CI, 0.63–0.97) for contoured BTVs. Furthermore, inter-observer agreement of GTV0 was similar prior to manual adjustment ( $\text{ICC} = 0.82$ ; 95% CI, 0.62–0.96). It should be noted that the CoV of GTV0 compared to the BTV increased in 3/6 of the benchmarking cases, although this increase was not greater than 4% (Supplementary Material 2 Table S2). To assess the impact of the resubmission process, the ICC was calculated on

initial contours only, which was found to be poor to excellent ( $\text{ICC} = 0.69$ ; 95% CI, 0.44–0.93). The resubmission process caused a marked increase in the ICC of 0.13 (0.69 to 0.82), with the lower bound of the 95% CI increasing from 0.44 to 0.63 which displays a quantitative improvement in NMP agreement. Contouring of the background resulted in reasonable variability in uptake with  $\text{SUV}_{\text{mean}}$  median CoV = 5.81% (range, 4.78–6.32%).

Pairwise analysis for the BTV revealed good overlap agreement across all cases ( $\text{DSC} = 0.84 \pm 0.09$ ), with every case reporting a mean  $\text{DSC} > 0.8$ , except for FET3CASE2 ( $\text{DSC} = 0.77 \pm 0.09$ ). HD was on average  $> 10 \text{ mm}$  for each case, with FET3CASE2 exceeding  $20 \text{ mm}$  ( $\text{HD} = 15.78 \pm 8.30 \text{ mm}$  across all cases), reaching over  $40 \text{ mm}$  in some pairwise comparisons. Although, HD is sensitive to outliers and the presence of small discrepant islands of uptake in the delineated BTV can increase pairwise distance drastically. However, average boundary differences revealed that they rarely exceeded  $3 \text{ mm}$ , with  $\text{MASD} = 1.47 \pm 1.36 \text{ mm}$  exhibited across all cases. FET3CASE2 showed the greatest separation of boundaries with  $\text{MASD} = 3.41 \pm 1.95 \text{ mm}$ . Overall, pairwise comparison shows that BTV




**Table 2** Mean, standard deviation (SD), and coefficient of variation (CoV) of BTV,  $TBR_{max}$ ,  $TBR_{mean}$ , and pairwise DSC, HD, and MASD for the six nuclear medicine credentialing cases of the FIG study

		FET1CASE1	FET1CASE2	FET1CASE3	FET3CASE1	FET3CASE2	FET3CASE3
Volume	Mean (cm <sup>3</sup> )	34.13	64.69	17.99	44.17	68.32	14.78
	SD (cm <sup>3</sup> )	8.13	7.76	4.29	8.40	20.56	2.84
	CoV (%)	23.83	12.00	23.87	19.01	30.10	19.23
$TBR_{max}$	Mean	4.54	5.86	3.15	3.15	4.67	5.43
	SD	0.29	0.29	0.21	0.17	0.25	0.35
	CoV (%)	6.30	5.01	6.68	5.47	5.40	6.36
$TBR_{mean}$	Mean	2.15	2.33	2.04	2.03	2.32	2.56
	SD	0.11	0.08	0.10	0.13	0.12	0.09
	CoV (%)	5.29	3.38	4.73	6.34	5.33	3.37
DSC	Mean	0.85	0.88	0.85	0.85	0.77	0.84
	SD	0.08	0.05	0.09	0.08	0.09	0.08
	CoV (%)	9.72	5.36	10.29	9.03	11.64	9.70
HD	Mean (mm)	15.14	12.78	10.15	14.59	23.37	18.09
	SD (mm)	7.84	2.74	5.65	6.25	9.40	8.89
	CoV (%)	51.76	21.45	55.69	42.81	40.22	49.14
MASD	Mean (mm)	1.24	0.77	1.09	1.10	3.41	1.20
	SD (mm)	0.82	0.34	0.78	0.68	1.95	0.77
	CoV (%)	65.62	44.55	71.21	62.01	57.32	63.89


analysis of FET1CASE2 demonstrated the best agreement, whereas FET3CASE2 had the worst (Fig. 3). Data relating to DSC, HD, MASD, and background  $SUV_{mean}$  of all NMP contours can be found in Fig. 4 and in the supplementary material (Supplementary Material 2, Tables S3–S6, Figs. S1–S3).

## Discussion

The increased utilisation of FET PET and the incorporation of semi-quantitative parameters for clinical evaluation have highlighted the need for a greater understanding of how


**Fig. 2** Boxplots showing the distribution of NMP BTVs (left),  $TBR_{max}$  (middle), and  $TBR_{mean}$  (right) grouped by each nuclear medicine credentialing case

**Fig. 3** Illustration of credentialing image FET1CASE2 that exhibited the best ( $DSC = 0.88 \pm 0.05$ ) agreement amongst NMPs (left) and credentialing image FET3CASE2 that showed the poorest ( $DSC = 0.77 \pm 0.09$ ) agreement (right). Superimposed NMP contours are shown in red. Discrepancy between NMPs when including the additional area of uptake (white arrow) in FET3CASE2 is likely the main source of variability in the pairwise analysis



NMPs interpret FET PET studies. Accurate tumour delineation and interpretation of FET PET are crucial for glioblastoma patient management, which includes assessment of newly diagnosed tumour for biopsy planning and surgical intervention, differential diagnosis at suspected progression, and treatment monitoring. The most frequent indication for FET PET scans being performed is at suspected tumour recurrence [35]. Although clinical evaluation primarily evaluates qualitative parameters and TBRs, the BTV also plays a role as a prognostic biomarker and for treatment response when comparing previous imaging timepoints [36, 37]. It is further useful to assess the clinical role of the BTV in radiotherapy planning and monitoring of glioma patients, as recently reviewed by the PET/RANO group [38].

We have performed the largest reported FET PET credentialing study, incorporating 21 NM specialists, across 10 different centres each undertaking analysis of 6 scans (126 total) to assess reporting performance and contour variability. The expert review and resubmission process demonstrated that the majority (86.7%) of significant errors were made by NMPs with no or minimal experience in FET PET studies and highlighted several key areas that required education and training, including manual adjustment of the final BTV, the adequate encapsulation of the white–grey matter junction in the background region, TAC type classification, and FET3 image interpretation. The BTV variability exhibited in this credentialing study was moderate to excellent as assessed by the ICC, with good



**Fig. 4** Boxplots visualising the distribution of pairwise Dice similarity coefficient (DSC) of each delineated structure, grouped by case. The biological tumour volume (BTV), GTV0 (volume obtained after threshold is

applied), and Static VOI are all generated as part of the delineation process. For each set of credentialing cases, spatial overlap is assessed by calculating the DSC for every pairwise combination of NMP contours

pairwise comparison between NMPs when assessing spatial overlap and boundary differences.

Both BTV over-contouring and background placement were primary reasons for FET1 violations and resubmissions. BTV under-contouring was mentioned in 12.5% of violations but was not present in any report where a resubmission was requested. Given the contouring protocol, under-contouring will most often occur when placing the initial sphere, which never resulted in a major violation. However, BTV over-contouring was far more common and was mentioned a total of 20 times across both FET1 and FET3 cases, usually resulting from unnecessary manual adjustments, nine of which mentioned NMPs failing to remove scalp uptake. Key assessment for the FET3 cases was interpretation, with error in TAC classification and image interpretation not concordant with expert being the primary sources of violations. Background violations were not mentioned in any FET3 reports where a resubmission was requested. Perhaps, since an error in background would directly impact  $TBR_{max}$ , it was not to a degree that interpretation would be significantly impacted. To further this point, an important threshold for interpretation is  $TBR_{max} > 2.3$  which no NMP fell below, as shown in Fig. 2 [17]. It should be noted that correct BTV delineation was not a strictly assessed criterion in the FET3 cases as it was in the FET1 cases, although correct delineation is important for the FIG study as NMPs will compare with previous imaging for response assessment and prognostic analysis. As such, there were four instances where an NMP's interpretation was considered acceptable, but their contoured regions were failed by the expert reviewer. Furthermore, although TAC classification and image interpretation were commented on equally when analysing FET3 violations, they occurred together in only six case reports. In many instances, an error when assigning TAC types did not coincide with an error in interpretation and vice versa. Regardless, TAC type misclassifications were a more frequent source of error in FET3 analysis, rather than abnormal  $SUV_{max}/TBR_{max}$  which was only mentioned by a reviewer once, with another resulting from a technical error related to the dataset rather than a user error.

In an inter-observer study with 30 newly diagnosed high-grade glioma (HGG) cases, DSC overlap of FET PET was found to be 0.922 (95% CI, 0.910–0.934), with excellent volume agreement (ICC=0.986; 95% CI, 0.975–0.993) [39]. Excellent agreement was also found segmenting on T1c (ICC=0.969; 95%CI, 0.944–0.984) and good to excellent on T2-FLAIR (ICC=0.929; 95% CI, 0.871–0.964). A 1.6 TBR threshold was applied to a 30-mm margin around the MRI-based GTV, whereas, in this study, a spherical VOI was placed around the suspected tumour volume. The placement of the initial spherical VOI was an overt source of variability

found in the contours of FET3CASE2, as the initial sphere placed by NMPs covered the additional area of uptake to varying degrees (Supplementary Material 2 Fig. S4). Furthermore, a study using 40%  $SUV_{max}$  to delineate the BTV reported excellent inter-observer agreement (ICC=0.9; no CIs given) across 19 post-operative HGG cases [40]. Lastly, in a study of 3,4-dihydroxy-6-[ $^{18}F$ ]-fluoro-L-phenylalanine (FDOPA) PET of 19 HGG cases, the mean Jaccard index of PET inter-observer volume overlap was  $0.42 \pm 0.22$  [41]. As this is equivalent to a mean DSC of 0.59, the lower overlap agreement when compared to this study is likely due to the manual FDOPA PET delineation methodology.

Variability of  $TBR_{max}$  and  $TBR_{mean}$  was similar as measured by the CoV, although  $TBR_{mean}$  exhibited a noticeable number of outlier values which warranted further investigation. Outliers far below the median in each case were caused by a manual addition of volume to GTV0 after thresholding to give the final BTV. In a particular instance, an NMP returned a  $TBR_{mean} < 1.6$  when assessing FET3CASE1, which was due to the manual inclusion of a central area of low activity/necrosis. It is expected that several outliers would be avoided if NMPs were restricted from adding more volume to GTV0 when finalising the BTV, as this approach is likely to include voxels with a  $TBR < 1.6$ . Finally, outliers far above the median in each case tended to coincide with background assessments that had relatively low  $SUV_{mean}$ , although this occurred less frequently (Supplementary Material 2 Fig. S5).

A background measurement that is robust to intra- and inter-observer variability is key to adequately delineate a volume that separates malignant uptake from normal uptake within the brain. Furthermore, variability in  $TBR_{max}$  typically relies on the mean background activity acquired as we found that all NMPs obtained the same  $SUV_{max}$  within their delineated BTVs. Although, there may be a small possibility, in certain cases, where  $SUV_{max}$  is peripheral to the central tumour area, which could be missed when applying the initial sphere. The crescent-shaped volume used in this study for background assessment is based on the work by Unterrainer et al. (2017) [28] which reported  $SUV_{mean}$  median CoV of 2.14% (range, 1.05–7.23%) evaluated by six readers across 20 scans. In this study, the  $SUV_{mean}$  median CoV was higher at 5.81%, although the range of values reported here (4.78–6.32%) is within said range. It should be noted that the methodology in drawing the crescent-shaped volume reported by Unterrainer et al. differed when compared to the FIG workflow. In the FIG workflow, NMPs are only required to draw the background region of interest on one slice, which then generates a 3D cylindrical “tube” as the crescent-shape is drawn (Supplementary Material 2 Fig. S6), whereas the methodology by Unterrainer et al. involved the drawing of a crescent-shaped ROI on six consecutive axial slices which were fused to form the VOI. This is perhaps a



source of difference in the inter-observer variability reported here. Another study has also reported a methodology for background assessment using a semi-automatic generation of mirror-image reference regions, assessed on recurrent GBM patients, to remove arbitrary volume definitions that are part of the delineation process [42]. Reported inter-observer variability in background  $SUV_{mean}$  when using a guided crescent-shape approach was also lower (median CoV 2.80%; range, 1.00–4.35%), but variability for the BTV (median CoV 14.37%; range, 5.03–36.30%) was not far from that reported in this study. Furthermore, automatic lesion detection of gliomas has been explored using a 3D U-Net [43], with reported DSC up to 0.8231 on the validation set, similar to the level of mean inter-observer overlap found in this study. As a potential approach, the automatic placement of the initial spherical VOI around the tumour volume and background contour could be investigated, with an NMP making manual adjustment where needed, to streamline the clinical workflow.

In comparison to PET, studies have also assessed inter-observer agreement in the delineation of gliomas on MRI. In a longitudinal study of inter-observer agreement, expert segmentation of GBM enhancing tumour elements on T1c was excellent for pre-operative MRI, good to excellent for post-operative MRI, although with low spatial overlap, and good to excellent agreement on MRI at progression [44]. A definitive decrease in volume agreement was observed for non-enhancing GBM tumour elements segmented on T2/FLAIR images in the post-operative setting, reporting poor to moderate agreement. Visser et al. (2019) [44] noted that agreement on absence of residual enhancing tumour on post-operative MRI in several patients may have contributed to a high ICC. Additionally, a study of 8 GBM cases on delineating enhancing tumour on T1c exhibited excellent agreement on pre-operative MRI and poor to good agreement on post-operative MRI [45]. Lastly, mean DSC was found to be  $\geq 0.93$  when assessing intra-observer, inter-observer, and between software semi-automatic segmentation agreements, in a study of 18 pre-operative GBM cases [46]. Structural MRI combined with the physiological information provided by FET PET may help to improve spatial overlap of physician contours, particularly in the post-operative setting.

One potential limitation of the credentialing process is the relatively small number of patient cases that were evaluated. The large number of reporting NMPs and participating centres would have made the inclusion of more cases for qualitative and semi-quantitative analysis impractical. However, from the credentialing program, a workflow has been developed that can be used in a potential audit on a larger number of live cases following completion of the FIG study. Although the cohort was small and included only GBM cases, the choice of FET scans used for credentialing

ranged in terms of lesion location, extent of uptake, tumour size, and diagnosis. There is a possibility that the imaging manual provided for NMPs who performed the analysis was not sufficiently detailed, leading to the errors in interpretation, although feedback from the central expert reviewers was able to correct these errors in subsequent analysis. The development of more detailed instruction manuals, or training videos, may address this important point in larger studies or for routine clinical implementation of FET PET studies. There were slight differences in time of acquisition and image reconstruction between the FET1 and FET3 sets of cases; however, we do not believe this substantially impacted on the interpretation of the cases used. Furthermore, axial T2 or FLAIR alongside axial T1c was available in the FET1 cases, whereas only axial T1c was available in the FET3 cases. Sources of discrepancy between this study and others may include that, upon expert review, some NMP contours may have had errors that were noted but were not extensive enough to cause a resubmission, which would have reduced agreement. Our study also used a 1.6 TBR threshold which was established in untreated gliomas, and whilst it is commonly used in FET PET interpretation, an alternative threshold of 1.7–1.8 has been proposed for the assessment of relapsed GBM [47]. Although no other study reported a review and resubmission process, it was a necessary part of credentialing, as some NMPs from participating centres were unfamiliar with FET PET contouring (majority with zero/minimal prior experience). This process identified sources of NMP deviation from protocol when contouring on FET PET, across all participating centres, which could be corrected prior to patient recruitment as part of the prospective phase.

## Conclusion

The FIG credentialing program was undertaken to evaluate NMP variability in FET PET lesion delineation, and to increase expertise and standardisation of semi-quantitative analysis, enabling sites participating in the FIG study across multiple centres to commence recruitment. BTV volume agreement was found to be moderate to excellent as assessed by the ICC. Pairwise analysis revealed good spatial overlap and boundary agreement across all cases, and it was found that placement of the initial spherical VOI can be an unexpected source of NMP disagreement in certain cases. Submissions primarily found sources of violations to result from manual BTV adjustment, placement of the background contour on the white–grey matter junction, TAC type classification, and image interpretation. The resubmission process addressed these sources of major violation which were passed accordingly. These will be important areas of focus in the analysis performed for the recruitment phase of the study.

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1007/s00259-023-06371-5>.

**Acknowledgements** The FIG study is supported by the Medical Research Future Fund (MRFF) (Grant No. MRF1152501), MRFF Australian Brain Cancer Mission: Innovative Trials Grant MRF9500003, Cure Brain Cancer Foundation, the Victorian Cancer Agency Centre for Research Excellence in Brain Cancer, Cyclotek, and Telix Pharmaceuticals. NB gratefully acknowledges the award of the RTP scholarship from the University of Western Australia. NB was supported by a Cancer Council WA PhD Top Up Scholarship. AMS is supported by NHMRC Investigator Grant No 1177837. Special thanks to Anita and Anthony Parise for their generous contribution to brain cancer research at Sir Charles Gairdner Hospital.

**Funding** Open Access funding enabled and organized by CAUL and its Member Institutions

## Declarations

**Ethics approval** Two studies from which patient data was used and reported in this research underwent respective, local ethics approval. These studies were performed in accordance with the “NHMRC Statement on Ethical Conduct in Human Research” (Commonwealth of Australia, 2007), the principles laid down by the 18th World Medical Assembly (Helsinki, 1964), and subsequent amendments.

**Consent to participate** All patients provided written informed consent prior to PET examinations included in this manuscript.

**Consent for publication** Not applicable.

**Conflict of interest** The authors declare no competing interests.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

## References

- Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. *Lancet Oncol*. 2009;10:459–66. [https://doi.org/10.1016/s1470-2045\(09\)70025-7](https://doi.org/10.1016/s1470-2045(09)70025-7).
- Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology working group. *J Clin Oncol*. 2010;28:1963–72. <https://doi.org/10.1200/JCO.2009.26.3541>.
- Overcast WB, Davis KM, Ho CY, Hutchins GD, Green MA, Graner BD, et al. Advanced imaging techniques for neuro-oncologic tumor diagnosis, with an emphasis on PET-MRI imaging of malignant brain tumors. *Curr Oncol Rep*. 2021;23:34. <https://doi.org/10.1007/s11912-021-01020-2>.
- Albert NL, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM, et al. Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. *Neuro Oncol*. 2016;18:1199–208. <https://doi.org/10.1093/neuonc/nov058>.
- Villanueva-Meyer JE, Mabray MC, Cha S. Current clinical brain tumor imaging. *Neurosurgery*. 2017;81:397–415. <https://doi.org/10.1093/neuros/nyx103>.
- Shukla G, Alexander GS, Bakas S, Nikam R, Talekar K, Palmer JD, et al. Advanced magnetic resonance imaging in glioblastoma: a review. *Chin Clin Oncol*. 2017;6:40. <https://doi.org/10.21037/cco.2017.06.28>.
- Pauleit D, Stoffels G, Bachofner A, Floeth FW, Sabel M, Herzog H, et al. Comparison of 18F-FET and 18F-FDG PET in brain tumors. *Nucl Med Biol*. 2009;36:779–87.
- Lohmann P, Herzog H, Rota Kops E, Stoffels G, Judov N, Filss C, et al. Dual-time-point O-(2-[(18F)fluoroethyl]-L-tyrosine PET for grading of cerebral gliomas. *Eur Radiol*. 2015;25:3017–24. <https://doi.org/10.1007/s00330-015-3691-6>.
- Verger A, Stoffels G, Bauer EK, Lohmann P, Blau T, Fink GR, et al. Static and dynamic (18F)-FET PET for the characterization of gliomas defined by IDH and 1p/19q status. *Eur J Nucl Med Mol Imaging*. 2018;45:443–51. <https://doi.org/10.1007/s00259-017-3846-6>.
- Rapp M, Heinzel A, Galldiks N, Stoffels G, Felsberg J, Ewelt C, et al. Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma. *J Nucl Med*. 2013;54:229–35. <https://doi.org/10.2967/jnumed.112.109603>.
- Harat M, Malkowski B, Makarewicz R. Pre-irradiation tumour volumes defined by MRI and dual time-point FET-PET for the prediction of glioblastoma multiforme recurrence: a prospective study. *Radiother Oncol*. 2016;120:241–7. <https://doi.org/10.1016/j.radonc.2016.06.004>.
- Henriksen OM, Larsen VA, Muhic A, Hansen AE, Larsson HBW, Poulsen HS, et al. Simultaneous evaluation of brain tumour metabolism, structure and blood volume using [(18F)-fluoroethyltyrosine (FET) PET/MRI: feasibility, agreement and initial experience. *Eur J Nucl Med Mol Imaging*. 2016;43:103–12. <https://doi.org/10.1007/s00259-015-3183-6>.
- Niyazi M, Geisler J, Siefert A, Schwarz SB, Ganswindt U, Garny S, et al. FET-PET for malignant glioma treatment planning. *Radiother Oncol*. 2011;99:44–8. <https://doi.org/10.1016/j.radonc.2011.03.001>.
- Song S, Cheng Y, Ma J, Wang L, Dong C, Wei Y, et al. Simultaneous FET-PET and contrast-enhanced MRI based on hybrid PET/MR improves delineation of tumor spatial biodistribution in gliomas: a biopsy validation study. *Eur J Nucl Med Mol Imaging*. 2020;47:1458–67. <https://doi.org/10.1007/s00259-019-04656-2>.
- Piroth MD, Pinkawa M, Holy R, Klotz J, Schaaf S, Stoffels G, et al. Integrated boost IMRT with FET-PET-adapted local dose escalation in glioblastomas. *Strahlenther Onkol*. 2012;188:334–9. <https://doi.org/10.1007/s00066-011-0060-5>.
- Galldiks N, Dunkl V, Ceccon G, Tscherpel C, Stoffels G, Law I, et al. Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustine. *Eur J Nucl Med Mol Imaging*. 2018;45:2377–86. <https://doi.org/10.1007/s00259-018-4082-4>.
- Galldiks N, Dunkl V, Stoffels G, Hutterer M, Rapp M, Sabel M, et al. Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET. *Eur J Nucl Med Mol Imaging*. 2015;42:685–95. <https://doi.org/10.1007/s00259-014-2959-4>.
- Skoblar Vidmar M, Doma A, Smrdel U, Zevnik K, Studen A. The value of FET PET/CT in recurrent glioma with a different IDH mutation status: the relationship between imaging and molecular biomarkers. *Int J Mol Sci*. 2022;23:6787.

19. Werner J-M, Stoffels G, Lichtenstein T, Borggrefe J, Lohmann P, Ceccon G, et al. Differentiation of treatment-related changes from tumour progression: a direct comparison between dynamic FET PET and ADC values obtained from DWI MRI. *Eur J Nucl Med Mol Imaging*. 2019;46:1889–901.
20. Steidl E, Langen K-J, Hmeidan SA, Polomac N, Filss CP, Galldiks N, et al. Sequential implementation of DSC-MR perfusion and dynamic [18F] FET PET allows efficient differentiation of glioma progression from treatment-related changes. *Eur J Nucl Med Mol Imaging*. 2021;48:1956–65.
21. Galldiks N, Langen KJ, Holy R, Pinkawa M, Stoffels G, Nolte KW, et al. Assessment of treatment response in patients with glioblastoma using O-(2-[18F-fluoroethyl]-L-tyrosine) PET in comparison to MRI. *J Nucl Med*. 2012;53:1048–57. <https://doi.org/10.2967/jnumed.111.098590>.
22. Jansen NL, Suchorska B, Wenter V, Schmid-Tannwald C, Todica A, Eigenbrod S, et al. Prognostic significance of dynamic 18F-FET PET in newly diagnosed astrocytic high-grade glioma. *J Nucl Med*. 2015;56:9–15. <https://doi.org/10.2967/jnumed.114.144675>.
23. Poulsen SH, Urup T, Grunnet K, Christensen IJ, Larsen VA, Jensen ML, et al. The prognostic value of FET PET at radiotherapy planning in newly diagnosed glioblastoma. *Eur J Nucl Med Mol Imaging*. 2017;44:373–81. <https://doi.org/10.1007/s00259-016-3494-2>.
24. Ceccon G, Lohmann P, Werner J-M, Tscherpel C, Dunkl V, Stoffels G, et al. Early treatment response assessment using 18F-FET PET compared with contrast-enhanced MRI in glioma patients after adjuvant temozolomide chemotherapy. *J Nucl Med*. 2021;62:918–25.
25. Rosen J, Stoffels G, Lohmann P, Bauer EK, Werner J-M, Wollring M, et al. Prognostic value of pre-irradiation FET PET in patients with not completely resectable IDH-wildtype glioma and minimal or absent contrast enhancement. *Sci Rep*. 2021;11:1–9.
26. Galldiks N, Langen KJ, Albert NL, Chamberlain M, Soffietti R, Kim MM, et al. PET imaging in patients with brain metastasis-report of the RANO/PET group. *Neuro Oncol*. 2019;21:585–95. <https://doi.org/10.1093/neuonc/noz003>.
27. Koh E-S, Gan HK, Senko C, Francis RJ, Ebert M, Lee ST, et al (2023) [18F]-fluoroethyl-L-tyrosine (FET) in glioblastoma (FIG) TROG 18.06 study: protocol for a prospective, multicentre PET/CT trial. *BMJ Open* 13:e071327. <https://doi.org/10.1136/bmjopen-2022-071327>
28. Unterrainer M, Vettermann F, Brendel M, Holzgreve A, Lifschitz M, Zahringer M, et al. Towards standardization of (18F)-FET PET imaging: do we need a consistent method of background activity assessment? *EJNMMI Res*. 2017;7:48. <https://doi.org/10.1186/s13550-017-0295-y>.
29. Pauleit D, Floeth F, Hamacher K, Riemenschneider MJ, Reifenberger G, Muller HW, et al. O-(2-[18F]Fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. *Brain*. 2005;128:678–87. <https://doi.org/10.1093/brain/awh399>.
30. Calcagni ML, Galli G, Giordano A, Taralli S, Anile C, Niesen A, et al. Dynamic O-(2-[18F] fluoroethyl)-L-tyrosine (F-18 FET) PET for glioma grading: assessment of individual probability of malignancy. *Clin Nucl Med*. 2011;36:841–7.
31. Taha AA, Hanbury A. Metrics for evaluating 3D medical image segmentation: analysis, selection, and tool. *BMC Med Imaging*. 2015;15:1–28.
32. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. *Psychol Bull*. 1979;86:420.
33. McGraw KO, Wong SP. Forming inferences about some intraclass correlation coefficients. *Psychol Methods*. 1996;1:30.
34. Koo TK, Li MY. A guideline of selecting and reporting intraclass correlation coefficients for reliability research. *J Chiropr Med*. 2016;15:155–63.
35. Heinzel A, Dedic D, Galldiks N, Lohmann P, Stoffels G, Filss CP, et al. Two decades of brain tumour imaging with O-(2-[18F] fluoroethyl)-L-tyrosine PET: the Forschungszentrum Jülich experience. *Cancers*. 2022;14:3336.
36. Suchorska B, Jansen NL, Linn J, Kretzschmar H, Janssen H, Eigenbrod S, et al. Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM. *Neurology*. 2015;84:710–9.
37. Suchorska B, Unterrainer M, Biczok A, Sosnova M, Forbrig R, Bartenstein P, et al. 18 F-FET-PET as a biomarker for therapy response in non-contrast enhancing glioma following chemotherapy. *J Neurooncol*. 2018;139:721–30.
38. Galldiks N, Niyazi M, Grosu AL, Kocher M, Langen K-J, Law I, et al. Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients-a report of the PET/RANO group. *Neuro Oncol*. 2021;23:881–93.
39. Dissaux B, Mazouz Fatmi D, Ognard J, Allard B, Keromnes N, Latreche A, et al. Radiotherapy target volume definition in newly diagnosed high-grade glioma using 18F-FET PET imaging and multiparametric MRI: an inter observer agreement study. *Tomography*. 2022;8:2030–41.
40. Weber DC, Zilli T, Buchegger F, Casanova N, Haller G, Rouzaud M et al. [(18F)Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma. *Radiat Oncol*. 2008;3. <https://doi.org/10.1186/1748-717X-3-44>.
41. Kosztyla R, Chan EK, Hsu F, Wilson D, Ma R, Cheung A et al. High-grade glioma radiation therapy target volumes and patterns of failure obtained from magnetic resonance imaging and 18F-FDOPA positron emission tomography delineations from multiple observers. *Int J Radiation Oncology\* Biology\* Physics*. 2013;87:1100–6.
42. Brighi C, Puttick S, Li S, Keall P, Neville K, Waddington D, et al. A novel semiautomated method for background activity and biological tumour volume definition to improve standardisation of 18F-FET PET imaging in glioblastoma. *EJNMMI physics*. 2022;9:1–13.
43. Blanc-Durand P, Van Der Gucht A, Schaefer N, Itti E, Prior JO. Automatic lesion detection and segmentation of 18F-FET PET in gliomas: a full 3D U-Net convolutional neural network study. *PLoS One*. 2018;13:e0195798. <https://doi.org/10.1371/journal.pone.0195798>.
44. Visser M, Müller D, van Duijn R, Smits M, Verburg N, Hendriks E, et al. Inter-rater agreement in glioma segmentations on longitudinal MRI. *NeuroImage Clinical*. 2019;22:101727.
45. Kubben PL, Postma AA, Kessels AGH, Van Overbeeke JJ, Van Santbrink H. Intraobserver and interobserver agreement in volumetric assessment of glioblastoma multiforme resection. *Neurosurgery*. 2010;67:1329–34. <https://doi.org/10.1227/NEU.0b013e3181efbb08>.
46. Fyllingen EH, Stensjøen AL, Berntsen EM, Solheim O, Reinertsen I. Glioblastoma segmentation: comparison of three different software packages. *PLoS ONE*. 2016;11. <https://doi.org/10.1371/journal.pone.0164891>.
47. Popp I, Bott S, Mix M, Oehlke O, Schimek-Jasch T, Nieder C, et al. Diffusion-weighted MRI and ADC versus FET-PET and Gd1w-MRI for gross tumor volume (GTV) delineation in re-irradiation of recurrent glioblastoma. *Radiother Oncol*. 2019;130:121–31.

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## Authors and Affiliations

Nathaniel Barry<sup>1,2</sup>  · Roslyn J. Francis<sup>3,4</sup> · Martin A. Ebert<sup>1,2,4,5</sup> · Eng-Siew Koh<sup>6,7</sup> · Pejman Rowshanfarzad<sup>1,2</sup> · Ghulam Mubashar Hassan<sup>1</sup> · Jake Kendrick<sup>1,2</sup> · Hui K. Gan<sup>8,9,10,11</sup> · Sze T. Lee<sup>9,10,11,12</sup> · Eddie Lau<sup>12,13,14</sup> · Bradford A. Moffat<sup>14</sup> · Greg Fitt<sup>13</sup> · Alisha Moore<sup>15</sup> · Paul Thomas<sup>16,17</sup> · David A. Pattison<sup>16,17</sup> · Tim Akhurst<sup>10,18</sup> · Ramin Alipour<sup>10,18</sup> · Elizabeth L. Thomas<sup>3</sup> · Edward Hsiao<sup>19</sup> · Geoffrey P. Schembri<sup>19</sup> · Peter Lin<sup>7,20</sup> · Tam Ly<sup>20</sup> · June Yap<sup>20</sup> · Ian Kirkwood<sup>21,22</sup> · Wilson Vallat<sup>21</sup> · Shahroz Khan<sup>23</sup> · Dayanethee Krishna<sup>23</sup> · Stanley Ngai<sup>24</sup> · Chris Yu<sup>24</sup> · Scott Beuzeville<sup>25</sup> · Tow C. Yeow<sup>25</sup> · Dale Bailey<sup>19,26</sup> · Olivia Cook<sup>15</sup> · Angela Whitehead<sup>15</sup> · Rachael Dykij<sup>15</sup> · Alana Rossi<sup>15</sup> · Andrew Grose<sup>15</sup> · Andrew M. Scott<sup>9,10,11,12</sup>

<sup>1</sup> School of Physics, Mathematics and Computing, University of Western Australia, WA, Crawley, Australia

<sup>2</sup> Centre for Advanced Technologies in Cancer Research (CATCR), WA, Perth, Australia

<sup>3</sup> Department of Nuclear Medicine, Sir Charles Gairdner Hospital, Nedlands, WA, Australia

<sup>4</sup> Australian Centre for Quantitative Imaging, Medical School, University of Western Australia, Crawley, WA, Australia

<sup>5</sup> Department of Radiation Oncology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia

<sup>6</sup> Department of Radiation Oncology, Liverpool and Macarthur Cancer Therapy Centres, Liverpool, NSW, Australia

<sup>7</sup> South Western Sydney Clinical School, UNSW Medicine, University of New South Wales, Liverpool, NSW, Australia

<sup>8</sup> Department of Medical Oncology, Austin Hospital, Melbourne, VIC, Australia

<sup>9</sup> Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia

<sup>10</sup> Department of Medicine, University of Melbourne, Melbourne, VIC, Australia

<sup>11</sup> School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia

<sup>12</sup> Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia

<sup>13</sup> Department of Radiology, Austin Health, Melbourne, VIC, Australia

<sup>14</sup> Department of Radiology, University of Melbourne, Melbourne, VIC, Australia

<sup>15</sup> Trans Tasman Radiation Oncology Group (TROG Cancer Research), University of Newcastle, Callaghan, NSW, Australia

<sup>16</sup> Department of Nuclear Medicine, Royal Brisbane and Women's Hospital, Herston, QLD, Australia

<sup>17</sup> Faculty of Medicine, University of Queensland, St Lucia, QLD, Australia

<sup>18</sup> The Sir Peter MacCallum Department of Oncology, Melbourne, VIC, Australia

<sup>19</sup> Department of Nuclear Medicine, Royal North Shore Hospital, St Leonards, NSW, Australia

<sup>20</sup> Department of Nuclear Medicine, Liverpool Hospital, Liverpool, NSW, Australia

<sup>21</sup> Department of Nuclear Medicine, Royal Adelaide Hospital, Adelaide, SA, Australia

<sup>22</sup> Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA, Australia

<sup>23</sup> Department of Nuclear Medicine, Canberra Hospital, Woden, ACT, Australia

<sup>24</sup> Department of Nuclear Medicine, Princess Alexandra Hospital, Woolloongabba, QLD, Australia

<sup>25</sup> Department of Nuclear Medicine, St George Hospital, Kogarah, NSW, Australia

<sup>26</sup> Faculty of Medicine 7 Health, University of Sydney, Sydney, NSW, Australia